Patents Examined by Terra Cotta Gibbs
  • Methods and compositions for inhibiting the proliferation of cancer cells
    Patent number: 8415315
    Abstract: A method of decreasing the expression of LIM kinase 1 in a cancer cell comprising; providing an oligonucleotide consisting of the sequence of SEQ ID NO: 1; providing a cancer cell comprising an mRNA encoding LIM kinase 1; and introducing the oligonucleotide into the cancer cell, wherein the oligonucleotide decreases the expression of LIM kinase 1 in the cancer cell. The method also provides compositions of an antisense RNA LIM kinase 1 that can be administered to an individual for the purpose of inhibiting a protein kinase pathway and which further comprises methods for treating and monitoring the proliferation and metastasis of cancer cells. A kit may be used in the detection and treatment of cancer.
    Type: Grant
    Filed: February 16, 2010
    Date of Patent: April 9, 2013
    Assignee: University of Central Florida Research Foundation, Inc.
    Inventor: Ratna Chakrabarti
  • Method for increasing bone mass
    Patent number: 8415316
    Abstract: The present invention features methods for promoting the differentiation of osteoblast bone forming cells to a mineralization phenotype and increasing bone mass using inhibitors of Brahma. Subjects benefiting from such treatment may have non-union fractures, osteopenia or osteoporosis, osteosarcoma, or a bone graft or bone fusion or orthopedic and dental implants, osteolytic bone disease, skeletal defects or deficiencies or periodontal disease.
    Type: Grant
    Filed: August 6, 2010
    Date of Patent: April 9, 2013
    Assignee: University of Medicine and Dentistry of New Jersey
    Inventors: Elizabeth Moran, Stephen Flowers
  • Methods for treating multiple sclerosis using antisense oligonucleotides
    Patent number: 8415314
    Abstract: A method for treating a patient suffering from multiple sclerosis, particularly a relapsing form of multiple sclerosis, comprising periodically administering a pharmaceutical composition comprising a therapeutically effective amount of OLIGONUCLEOTIDE 1 to the patient, thereby treating the patient.
    Type: Grant
    Filed: June 23, 2009
    Date of Patent: April 9, 2013
    Assignees: Antisense Therapeutics Limited, Teva Pharmaceutical Industries, Ltd.
    Inventors: Ety Klinger, Shoshi Tessler, Hussein Hallak, George Tachas, Mark Paul Diamond
  • Method of regulating gene expression
    Patent number: 8409796
    Abstract: The present invention relates, in general, to gene expression and, in particular, to a method of inhibiting the expression of a target gene and to constructs suitable for use in such a method.
    Type: Grant
    Filed: January 23, 2012
    Date of Patent: April 2, 2013
    Assignee: Duke University
    Inventors: Bryan R. Cullen, Yan Zeng
  • Compositions and methods for treating cancer, inhibiting proliferation, and inducing cell death
    Patent number: 8410070
    Abstract: Quadruplex-forming guanine-rich nucleic acid sequences are useful in compositions and methods for inhibiting cellular growth and proliferation and inducing cell death. Compositions for treating a patient are provided, including (i) a safe and effective amount of a sequence having at least 80% nucleic acid identity with a guanine-rich promoter gene oligonucleotide (GPGO), and (ii) a carrier, wherein the oligonucleotide forms at least one quadruplex.
    Type: Grant
    Filed: September 11, 2009
    Date of Patent: April 2, 2013
    Assignee: University of Louisville Research Foundation, Inc.
    Inventors: Donald M. Miller, Shelia Diann Thomas, Kara Joyce Sedoris
  • Oligoribonucleotide inhibitors of Nrf2 and methods of use thereof for treatment of cancer
    Patent number: 8410069
    Abstract: The invention provides novel double stranded oligoribonucleotides that inhibit the Nrf2 gene. The invention also provides a pharmaceutical composition comprising one or more such oligoribonucleotides, and a vector capable of expressing the oligoribonucleotide. The present invention also relates to methods and compositions for treating or preventing the incidence or severity of a cancerous disease, particularly various lung cancers.
    Type: Grant
    Filed: October 8, 2010
    Date of Patent: April 2, 2013
    Assignee: Quark Pharmaceuticals, Inc.
    Inventor: Elena Feinstein
  • Isolated genomic polynucleotide fragments from the p15 region of chromosome 11 encoding human ribosomal protein L26 (RIBO26)
    Patent number: 8399642
    Abstract: Provided herein are isolated genomic polynucleotide fragments from the from the p15 region of chromosome 11 encoding human ribosomal protein L26 (RIBO26) and methods of use.
    Type: Grant
    Filed: September 24, 2011
    Date of Patent: March 19, 2013
    Assignee: Ryogen LLC
    Inventor: James Ryan
  • Isolated genomic polynucleotide fragments from the p15 region of chromosome 11
    Patent number: 8399638
    Abstract: Provided herein are isolated genomic polynucleotide fragments from the p15 arm of chromosome 11 and methods of use.
    Type: Grant
    Filed: September 18, 2011
    Date of Patent: March 19, 2013
    Assignee: Ryogen LLC
    Inventor: James Ryan
  • Isolated genomic polynucleotide fragments from the p15 region of chromosome 11 encoding human achaete-scute homolog 2 (HASH2)
    Patent number: 8399639
    Abstract: Provided herein are isolated genomic polynucleotide fragments from the p15 arm of chromosome 11 encoding HASH2 and methods of use.
    Type: Grant
    Filed: September 21, 2011
    Date of Patent: March 19, 2013
    Assignee: Ryogen LLC
    Inventor: James Ryan
  • Isolated genomic polynucleotide fragments from the p15 region of chromosome 11 encoding human SMS3
    Patent number: 8399640
    Abstract: Provided herein are isolated genomic polynucleotide fragments from the from the p15 region of chromosome 11 encoding human SMS3 (SMS3) and methods of use.
    Type: Grant
    Filed: September 21, 2011
    Date of Patent: March 19, 2013
    Assignee: Ryogen LLC
    Inventor: James Ryan
  • Isolated genomic polynucleotide fragments from the p15 region of chromosome 11 encoding human tumor suppressing subtransferable candidate 6 (TSSC6)
    Patent number: 8399641
    Abstract: Provided herein are isolated genomic polynucleotide fragments from the from the p15 region of chromosome 11 encoding human tumor suppressing subtransferable candidate 6 and methods of use.
    Type: Grant
    Filed: September 24, 2011
    Date of Patent: March 19, 2013
    Assignee: Ryogen LLC
    Inventor: James Ryan
  • Antidotes to antisense compounds
    Patent number: 8389488
    Abstract: The present invention relates to antisense antidote compounds and uses thereof. Such antidote compounds reduce the magnitude and/or duration of the antisense activity of an antisense compound.
    Type: Grant
    Filed: November 5, 2008
    Date of Patent: March 5, 2013
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Brett P. Monia, Andrew M. Siwkowski, Hong Zhang
  • G proteins in tumor growth and angiogenesis
    Patent number: 8383597
    Abstract: The invention provides an agent that reduces the expression of G?12 or G?13 polypeptide, as well as an agent that enhances G protein G?12 or G?13 expression and/or activity. An agent of the invention may be used to decrease or increase G protein G?12 or G?13 expression and/or activity thereby to treat or prevent the onset of a disease or condition associated with G?12 or G?13 expression and/or activity. The invention also provides a method for screening for an anti-cancer or anti-angiogenesis agent, as well as an agent that promotes angiogenesis.
    Type: Grant
    Filed: May 24, 2007
    Date of Patent: February 26, 2013
    Assignee: Cornell Research Foundation, Inc.
    Inventor: Xin-Yun Huang
  • Compositions and methods for non-parenteral delivery of oligonucleotides
    Patent number: 8377897
    Abstract: The present invention relates to compositions and methods which enhance the local and systemic uptake and delivery of oligonucleotides and nucleic acids via non-parenteral routes of administration. Pharmaceutical compositions comprising oligonucleotides disclosed herein include, for systemic delivery, emulsion and microemulsion formulations for a variety of applications and oral dosage formulations. It has also surprisingly been discovered that oligonucleotides may be locally delivered to colonic sites by rectal enemas and suppositories in simple solutions, e.g., neat or in saline. Such pharmaceutical compositions of oligonucleotides may further include one or more penetration enhancers for the transport of oligonucleotides and other nucleic acids across mucosal membranes.
    Type: Grant
    Filed: September 28, 2005
    Date of Patent: February 19, 2013
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Ching-Leou Teng, Phillip Dan Cook, Lloyd Tillman, Gregory E. Hardee, David J. Ecker, Muthiah Manoharan
  • Targeted double stranded RNA mediated cell killing
    Patent number: 8372818
    Abstract: A method of killing a specific target cell/tissue is disclosed. The method comprises exposing the specific target cell/tissue to a composition-of-matter which comprises a double stranded RNA molecule associated with a targeting moiety selected capable of targeting to the specific target cell/tissue, thereby killing the specific target cell/tissue.
    Type: Grant
    Filed: March 28, 2011
    Date of Patent: February 12, 2013
    Assignee: Yissum Research Development Company of the Hebrew Univiersity of Jerusalem
    Inventors: Alexei Shir, Alexander Levitzki
  • Method for inhibiting expression of a protein in a hepatocyte
    Patent number: 8367630
    Abstract: A method of screening a candidate compound for susceptibility to biliary excretion by a hepatocyte transport protein. In some embodiments the method can comprise inhibiting expression of the transport protein. Expression of the transport protein can be inhibited through introduction of a RNA having a sequence corresponding to a coding strand of the gene encoding the transport protein into the hepatocyte.
    Type: Grant
    Filed: August 28, 2009
    Date of Patent: February 5, 2013
    Assignee: The University of North Carolina at Chapel Hill
    Inventors: Xianbin Tian, Peijin Zhang, Kim L. R. Brouwer
  • Micrornas differentially expressed in cervical cancer and uses thereof
    Patent number: 8361714
    Abstract: The present invention concerns methods and compositions for identifying a miRNA profile for a particular condition, such as cervical disease, and using the profile in assessing the condition of a patient.
    Type: Grant
    Filed: September 12, 2008
    Date of Patent: January 29, 2013
    Assignee: Asuragen, Inc.
    Inventors: Sylvie Beaudenon-Huibregtse, Emmanuel Labourier, Laura Elizondo
  • Small interfering RNAs and methods for prevention, inhibition and/or treatment of malignant progression of breast cancer
    Patent number: 8361984
    Abstract: The invention found that overexpression and activation of ?9-nAChR are associated with tumorigenesis of breast cancer and create a number of small interfering RNAs to inhibit the expression of ?9-nAChR so as to inhibit breast cancer. Therefore, the invention provides small interfering RNAs (siRNAs) for inhibiting expression of ?9-nAChR so as to inhibit breast cancer, methods to prevent/inhibit/treat malignant progression of nicotine-derived-compound-induced breast cancer and method of determining malignant level of such breast cancer.
    Type: Grant
    Filed: February 14, 2011
    Date of Patent: January 29, 2013
    Assignee: Taipei Medical University
    Inventors: Chia-Hwa Lee, Ching-Shui Huang, Ching-Shyang Chen, Shih-Hsin Tu, Ying-Jan Wang, Yu-Jia Chang, Ka-Wai Tam, Po-Li Wei, Tzu-Chun Cheng, Jan-Show Chu, Li-Ching Chen, Chih-Hsiung Wu, Yuan-Soon Ho
  • Compositions and methods for inhibiting expression of a gene from the ebola virus
    Patent number: 8354390
    Abstract: The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of a gene from the Ebola virus.
    Type: Grant
    Filed: April 25, 2011
    Date of Patent: January 15, 2013
    Assignees: Alnylam Pharmaceuticals, Inc., The United States of America, as represented by the Secretary of the Army
    Inventors: Sina Bavari, Kelly Lyn Warfield, Pamela Tan, Anna Borodovsky, Tatiana Novobrantseva, Antonin de Fougerolles
  • Uses and compositions comprising miRNAs
    Patent number: 8343938
    Abstract: The cardiac-specific miRs, miR-133 and miR-1, are critical in determining hypertrophy of cardiac myocyte cells (CMC), and that restoration of levels of expression thereof can alleviate the symptoms of CMC hypertrophy.
    Type: Grant
    Filed: August 3, 2007
    Date of Patent: January 1, 2013
    Assignee: Consiglio Nazionale delle Ricerche
    Inventors: Cesare Peschle, Gianluigi Condorelli